Sat, Aug 23, 2014, 2:43 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OXiGENE, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • Minn_sea Minn_sea Oct 22, 1999 2:13 PM Flag

    Not a cure?

    TRYING;

    I agree with your analysis. SUGEN
    had the California rancher. Calyton Twigg is indeed a
    good and lucky result, especially for a Phase I trial.
    His carcinoma was unusual however. Most Thyroid
    tumors resolve well with surgery and radiation (often
    etopic).
    But, Claytons did not, making me think that
    there was some insideous driver behind his tumor's
    growth, perhaps an angiogenic driver, which was precisely
    targeted by the Combretastatin.

    Certainly, the
    potential/promise for VTAs is significant, even for just tumor
    burden reduction, resulting in quality of life
    enhancements for the unfortunate victoms of cancer. A key
    study will be a PHASEII for cytotoxin therapy
    potentiation by Combretastatin. Significant cytotoxin
    potentiation was seen in murine studies of anti-angiogenic
    agents. Clearly, that is a key point.

    Minn_sea...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
OXGN
2.12-0.03(-1.40%)Aug 22 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Keurig Green Mountain, Inc.
NasdaqGSFri, Aug 22, 2014 4:00 PM EDT
Amicus Therapeutics, Inc.
NasdaqGMFri, Aug 22, 2014 4:00 PM EDT